Prestwick Buyout Scores Huntington’s Drug For Biovail
This article was originally published in The Pink Sheet Daily
Executive Summary
Canadian company affirms prior deal that gave Ovation the U.S. rights to Xenazine.
You may also be interested in...
Santhera Licenses North American Rights For Parkinson's Drug To Biovail
The transaction is the Canadian drug maker's latest in a string of deals designed to increase its footing in the CNS market.
Santhera Licenses North American Rights For Parkinson's Drug To Biovail
The transaction is the Canadian drug maker's latest in a string of deals designed to increase its footing in the CNS market.
Biovail Locks Up Global Rights To Xenazine With Cambridge Deal
The $230 million deal doubles Biovail's investment in Xenazine and is the latest indication that there is more to this is Huntington's chorea therapy than meets the eye.